SciQuest Announces $30 Million Share Repurchase Program
Feb 25, 2016 21:15 pm UTC| Business
MORRISVILLE, N.C., Feb. 25, 2016 -- SciQuest, Inc. (Nasdaq:SQI), the leading public provider of spend management solutions delivering value beyond savings, today announced its Board of Directors has approved a share...
Monster Beverage Reports 2015 Fourth Quarter and Full Year Financial Results
Feb 25, 2016 21:10 pm UTC| Business
-- Fourth Quarter Net Sales Rise 6.6% to $645.4 Million;Fourth Quarter Net Income Increases 10.7% to $138.7 Million;Announces Repurchase Program of an Additional $1.75 Billion -- CORONA, Calif., Feb. 25, 2016 --...
SPX Reports Fourth Quarter and Full-Year 2015 Results
Feb 25, 2016 21:10 pm UTC| Business
Q4 Adjusted EPS* of $0.52; Strong Cash Flow and Reduced Leverage Continued Favorable Operating Performance for HVAC and Detection Measurement Segments, and Transformers Business; Offset by Power Generation CHARLOTTE,...
StoneCastle Financial Corp. Reports Fourth Quarter 2015 Results
Feb 25, 2016 21:10 pm UTC| Business
NEW YORK, Feb. 25, 2016 -- StoneCastle Financial Corp. (Nasdaq:BANX) (“StoneCastle Financial” or the “Company”), an investment company registered with the Securities and Exchange Commission (“SEC”), today announced...
Sizmek to Present at 28th Annual Roth Conference
Feb 25, 2016 21:10 pm UTC| Business
AUSTIN, Texas, Feb. 25, 2016 -- Sizmek Inc. (NASDAQ:SZMK), a global open ad management company that delivers multiscreen, multichannel campaigns, today announced that Ken Saunders, CFO will present at the 28th Annual...
Jones Soda Announces Fourth Quarter and Year-End 2015 Earnings Conference Call
Feb 25, 2016 21:10 pm UTC| Business
SEATTLE, Feb. 25, 2016 -- Jones Soda Co. (OTCQB:JSDA), a leader in the premium soda category and known for its unique branding and innovative marketing, today announced that it will host a conference call to discuss...
TESARO Announces Fourth-Quarter 2015 Operating Results
Feb 25, 2016 21:06 pm UTC| Business
U.S. commercial launch of VARUBI® (oral rolapitant) well underwayNiraparib Phase 3 NOVA results expected in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial of a PARP inhibitorNew...